Welcome to our dedicated page for Medline news (Ticker: MDLN), a resource for investors and traders seeking the latest updates and insights on Medline stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medline's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medline's position in the market.
Medline (NASDAQ: MDLN) priced an upsized initial public offering of 216,034,482 shares of Class A common stock at $29.00 per share, with underwriters granted a 30-day option for up to 32,405,172 additional shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on December 17, 2025, and the offering is expected to close on December 18, 2025. Net proceeds from 179,000,000 issued shares will repay outstanding senior secured term loan indebtedness; proceeds from 37,034,482 shares (and any option shares) will be used to purchase or redeem equity from certain pre-IPO owners.
Medline (MDLN) filed a registration statement on Form S-1 with the SEC on October 28, 2025 for a proposed initial public offering of common stock. The offering is subject to market and other conditions and the registration statement must become effective before any sale.
The number of shares, price range and final terms have not been determined. If completed, Medline intends to list on the Nasdaq Global Select Market under the symbol MDLN. Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are lead bookrunning managers.
FAQ
What is the current stock price of Medline (MDLN)?
